SCHEMBL189965

SCHEMBL189965

ON=Cc1ccc(OCc2ccccc2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.71
NPC1 O15118 5/20 0.71
SMN1; SMN2 Q16637 4/20 0.71
CASP3 P42574 2/20 0.71
SENP8 Q96LD8 2/20 0.71
SENP7 Q9BQF6 2/20 0.71
SENP6 Q9GZR1 2/20 0.71
MEN1 O00255 5/20 0.66
KMT2A Q03164 5/20 0.66
KDM4E B2RXH2 4/20 0.66
ALDH1A1 P00352 4/20 0.66
MAPT P10636 4/20 0.66
L3MBTL1 Q9Y468 3/20 0.66
LMNA P02545 2/20 0.66
GAA P10253 1/20 0.66
THRB P10828 1/20 0.66
PKM P14618 1/20 0.66
RECQL P46063 1/20 0.66
BLM P54132 1/20 0.66
PLEC Q15149 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL189964 1.00 RAB9A (0.71) RAB9ANPC1SMN1; SMN2CASP3SENP8
SCHEMBL2297148 1.00 RAB9A (0.71) RAB9ANPC1SMN1; SMN2CASP3SENP8
SCHEMBL12271842 0.83 NPC1 (0.72) RAB9ANPC1SMN1; SMN2CASP3SENP8
SCHEMBL15776771 0.83 NPC1 (0.77) RAB9ANPC1SMN1; SMN2CASP3SENP8
SCHEMBL12271844 0.83 NPC1 (0.72) RAB9ANPC1SMN1; SMN2CASP3SENP8
SCHEMBL15776773 0.83 NPC1 (0.77) RAB9ANPC1SMN1; SMN2CASP3SENP8
SCHEMBL17625509 0.83 MEN1 (0.66) RAB9ANPC1SMN1; SMN2CASP3SENP8
SCHEMBL10890571 0.82 MAOB (0.65) RAB9ANPC1SMN1; SMN2MEN1KMT2A
SCHEMBL6263881 0.82 MAOB (0.65) RAB9ANPC1SMN1; SMN2MEN1KMT2A
SCHEMBL9819902 0.82 KMT2A (0.59) RAB9ANPC1SMN1; SMN2CASP3SENP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113861069-B Preparation method of nitrile compound 陕西国际商贸学院 2023-06-16 CN disclosed
CN-113861069-A Preparation method of nitrile compound 陕西国际商贸学院 2021-12-31 CN disclosed
EP-2917188-B1 SOLID DISPERSIONS OF INSOLUBLE DRUG AND PREPARATION METHOD THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2018-08-01 EP disclosed
CN-105026378-B Solid dispersions of insoluble drugs and preparation method thereof 爱思开生物制药株式会社 2018-03-13 CN disclosed
US-9724335-B2 Solid dispersions of insoluble drug and preparation method thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2017-08-08 US disclosed
US-20170105973-A1 SOLID DISPERSIONS OF INSOLUBLE DRUG AND PREPARATION METHOD THEREOF SK BIOPHARMACEUTICALS CO., LTD. 2017-04-20 US disclosed
US-9566268-B2 Solid dispersions of insoluble drug and preparation method thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2017-02-14 US disclosed
US-20160346258-A1 SOLID DISPERSIONS OF INSOLUBLE DRUG AND PREPARATION METHOD THEREOF SK BIOPHARMACEUTICALS CO., LTD. 2016-12-01 US disclosed
US-9439970-B2 Solid dispersions of insoluble drug and preparation method thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2016-09-13 US disclosed
US-9290464-B2 Pharmaceutical composition for inhibiting apoptosis of neuron or neurodegeneration SK BIOPHARMACEUTICALS CO., LTD. (KR) 2016-03-22 US disclosed
CN-1729159-A Amide compounds and methods for controlling plant diseases SUMITOMO CHEMICAL CO (JP) 2006-02-01 CN disclosed
EP-1577290-A1 AMIDE COMPOUND AND METHOD OF CONTROLLING PLANT DISEASE WITH THE SAME Sumitomo Chemical Company, Limited (JP) 2005-09-21 EP disclosed
CN-1062559-C 4-aryl oxime ether quinazoline compound and synthesis method and application thereof UNIV NANKAI (CN) 2001-02-28 CN disclosed
CN-1121071-A Synthesis and activity of 4-aryl oxime ether quinazoline compound UNIV NANKAI (CN) 1996-04-24 CN disclosed
EP-0196184-B1 ARYL DERIVATIVES THE WELLCOME FOUNDATION LIMITED (GB) 1992-09-16 EP disclosed
US-5036157-A Hydroxamic acid derivatives, lipoxygenase and cyclooxygenase inhibitors, anticoagulants, antiinflammatory agents BURROUGHS WELLCOME CO. 1991-07-30 US disclosed
US-4977188-A Hydroamic acid derivatives BURROUGHS WELLCOME CO. (US) 1990-12-11 US disclosed
WO-1990001929-A1 NEW MEDICAL USE THE WELLCOME FOUNDATION LIMITED (GB) 1990-03-08 WO disclosed
US-4738986-A CYCLOOXYGENASE, LIDOXYGENASE INHIBITORS BURROUGHS WELLCOME CO. (US) 1988-04-19 US disclosed
EP-0196184-A2 Aryl derivatives THE WELLCOME FOUNDATION LIMITED (GB) 1986-10-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160346258-A1 SOLID DISPERSIONS OF INSOLUBLE DRUG AND PREPARATION METHOD THEREOF SI, CYP3A7, ABCG2 RAB9A 1475/4885NPC1 162/4885SMN1; SMN2 1287/4885
US-20170105973-A1 SOLID DISPERSIONS OF INSOLUBLE DRUG AND PREPARATION METHOD THEREOF SI, CYP3A7, ABCG2 RAB9A 1475/4885NPC1 162/4885SMN1; SMN2 1287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.